Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer

Hematology/Oncology Clinics of North America

Volumn 18, Issue 5, 2004, Pages 1121-1141

  Blackhall, Fiona H ^a   Shepherd, Frances A ^b,c  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; AE 941; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CELECOXIB; CILENGITIDE; CISPLATIN; COMBRETASTATIN; COMBRETASTATIN A1 PHOSPHATE; ENDOSTATIN; ERLOTINIB; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE; INTEGRIN; INTERFERON; MARIMASTAT; N ACETYLCOLCHINOL PHOSPHATE; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PACLITAXEL; PI 81; PRINOMASTAT; REBIMASTAT; SCH 21153; SEMAXANIB; SQUALAMINE; SUNITINIB; TANOMASTAT; THALIDOMIDE; UNCLASSIFIED DRUG; VANDETANIB;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CLINICAL TRIAL; DIAGNOSTIC IMAGING; FATIGUE; HUMAN; LUNG CARCINOMA; LUNG SMALL CELL CANCER; NAUSEA; PATHOGENESIS; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SIDE EFFECT; SMALL CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; STANDARD; SURVIVAL RATE; VOMITING;

ANGIOGENESIS INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CLINICAL TRIALS; HUMANS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEASE INHIBITORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 5044226921     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2004.06.005     Document Type: Review

References (93)

1. D. Schottenfeld Etiology and epidemiology of lung cancer H.I. Pass J.B. Mitchell D.H. Johnson A.T. Turrisi J.D. Minna Lung cancer: principles and practice 2nd edition 2000 Lippincott Williams and Wilkins Philadelphia 367 397
2. R.J. Ginsberg, and J.L. Port Surgical therapy of stage I and non-T3N0 stage II non-small cell lung cancer H.I. Pass J.B. Mitchell D.H. Johnson A.T. Turrisi J.D. Minna Lung cancer: principles and practice 2nd edition 2000 Lippincott Williams and Wilkins Philadelphia 682 693
3. R.F. DeVore, and D.H. Johnson Chemotherapy for small cell lung cancer H.I. Pass J.B. Mitchell D.H. Johnson A.T. Turrisi J.D. Minna Lung cancer: principles and practice 2nd edition 2000 Lippincott Williams and Wilkins Philadelphia 923 939
4. J. Folkman Tumor angiogenesis: therapeutic implications N Engl J Med 285 21 1971 1182 1186
5. P. Macchiariani, G. Fontanini, M.J. Hardin, F. Squartini, and C.A. Angeletti Relation of neovasularisation to metastasis of non-small cell lung cancer Lancet 340 8812 1992 145 146
6. A.P. Meert, M. Paesmans, B. Martin, P. Delmotte, T. Berghmans, and J.M. Verdebout The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis Br J Cancer 87 7 2002 694 701
7. P. Carmeliet, and R.K. Jain Angiogenesis in cancer and other disease Nat Med 1 1995 27 31
8. D.H. Harpole Jr, W.G. Richards, J.E. Herndon II, and D.J. Sugarbaker Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer Ann Thorac Surg 61 5 1996 1470 1476
9. I. Stamenkovic Extracellular matrix remodelling: the role of matrix metalloproteinases J Pathol 200 4 2003 448 464
10. S. Ylisirnio, M. Hoyhtya, and T. Turpeenniemi-Hujanen Serum matrix metalloproteinases-2, -9 and tissue inhibitors of metalloproteinases-1, -2 in lung cancerâ€"TIMP-1 as a prognostic marker Anticancer Res 20 2B 2000 1311 1316
11. E. Laack, A. Kohler, C. Kugler, T. Dierlamm, C. Knuffmann, and G. Vohwinkel Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer Ann Oncol 13 10 2002 1550 1557
12. A. Yuan, C.J. Yu, K.T. Luh, S.H. Kuo, Y.C. Lee, and P.C. Yang Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer J Clin Oncol 20 4 2002 900 910
13. D. Brattstrom, M. Bergqvist, P. Hesselius, A. Larsson, K. Lamberg, and J. Wernlund Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients Lung Cancer 37 1 2002 57 63
14. K.J. O'Byrne, M.I. Koukourakis, A. Giatromanolaki, G. Cox, H. Turley, and W.P. Steward Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer Br J Cancer 82 8 2000 1427 1432
15. M. Orditura, F. De Vita, G. Catalano, S. Infusino, E. Lieto, and E. Martinelli Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis J Interferon Cytokine Res 22 11 2002 1129 1135
16. J.M. Siegfried, L.A. Weissfeld, J.D. Luketich, R.J. Weyant, C.T. Gubish, and R.J. Landreneau The clinical significance of hepatocyte growth factor for non-small cell lung cancer Ann Thorac Surg 66 6 1998 1915 1918
17. F. Tanaka, S. Ishikawa, K. Yanagihara, R. Miyahara, Y. Kawano, and M. Li Expression of angiopoietins and its clinical significance in non-small cell lung cancer Cancer Res 62 23 2002 7124 7129
18. L. Boldrini, A. Calcinai, E. Samaritani, F. Pistolesi, A. Mussi, and M. Lucchi Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization Br J Cancer 83 4 2000 480 486
19. P. Thomas, R. Khokha, F.A. Shepherd, R. Feld, and M.S. Tsao Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer J Pathol 190 2 2000 150 156
20. K.M. Fong, Y. Kida, P.V. Zimmerman, and P.J. Smith TIMP1 and adverse prognosis in non-small cell lung cancer Clin Cancer Res 8 1996 1369 1372
21. M. Suzuki, T. Iizasa, E. Ko, M. Baba, Y. Saitoh, and K. Shibuya Serum endostatin correlates with progression and prognosis of non-small cell lung cancer Lung Cancer 35 1 2002 29 34
22. M. Yamaguchi, K. Sugio, K. Ondo, T. Yano, and K. Sugimachi Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer Lung Cancer 36 2 2002 143 150
23. M. Lucchi, A. Mussi, G. Fontanini, P. Faviana, A. Ribechini, and C.A. Angeletti Small cell lung carcinoma (SCLC): the angiogenic phenomenon Eur J Cardiothorac Surg 21 6 2002 1105 1110
24. M. Michael, B. Babic, R. Khokha, M. Tsao, J. Ho, and M. Pintilie Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer J Clin Oncol 17 6 1999 1802 1808
25. T. Ruotsalainen, H. Joensuu, K. Mattson, and P. Salven High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer Cancer Epidemiol Biomarkers Prev 11 11 2002 1492 1495
26. J.R. Fischer, M. Schindel, H. Bulzebruck, H. Lahm, P.H. Krammer, and P. Drings Long-term survival in small cell lung cancer patients is correlated with high interleukin-2 secretion at diagnosis J Cancer Res Clin Oncol 126 12 2000 730 733
27. M. Smylie, R. Mercier, D. Aboulafia, R. Tucker, P. Bonomi, and M. Collier Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer [abstract] Proc Am Soc Clin Oncol 20 2001 307a
28. D. Bissett, K. O'Byrne, J. von Pawel, R. Mercier, A. Price, and M. Nicolson Phase III study of the matrix metalloproteinase inhibitor prinomastat in combination with gemcitibine and cisplatin in non-small cell lung cancer [abstract] Proc. Am Soc Clin Oncol 21 2002 296a
29. P.D. Brown, and R. Giavazzi Matrix metalloproteinase inhibition: a review of anti-tumour activity Ann Oncol 6 10 1995 967 974
30. J.G. Naglich, M. Jure-Kunkel, E. Gupta, J. Fargnoli, A.J. Henderson, and A.C. Lewin Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor BMS-275291 Cancer Res 61 23 2001 8480 8485
31. P. Falardeau, P. Champagne, P. Poyet, C. Hariton, and E. Dupont Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials Semin Oncol 289 6 2001 620 625
32. M.S. Gordon, M. Talpaz, K. Margolin, E. Holmgren, G.W.J. Sledge, and R. Benjamin Phase I trial of recombinant human monoclonal anti-vascular endothelial growth factor (anti-VEGF MAB) in patients with metastatic cancer [abstract] Proc Am Soc Clin Oncol 18 1998 435a
33. K. Margolin, M.S. Gordon, M. Talpaz, G. Fyfe, W. Novotny, and D. Adelman Phase 1b trial of intravenous recombinant humanized monoclonal antibody (Mab) to vascular endothelial growth factor (rhuMAB VEGF) in combination with chemotherapy (CHrX) in patients with advanced cancer (CA): pharmacologic and long-term safety data [abstract] Proc. Am Soc Clin Oncol 18 1999 435a
34. R. DeVore, L. Fehrenbacher, R. Herbst, C. Langer, K. Kelly, and J. Gaudreault A randomized Phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage III/IV NSCLC Proc. Am Soc Clin Oncol 19 2000 485a
35. R. Gray, B.J. Giantonio, P.J. O'Dwyer, A. Sandler, K. Miller, and R.L. Comis The safety of adding angiogenesis inhibition into treatment for colorectal, breast, and lung cancer: The Eastern Cooperative Oncology Group's (ECOG) experience with bevacizumab (anti-VEGF) [abstract] Proc Am Soc Clin Oncol 22 2003 206
36. E.D. Mininberg, R.S. Herbst, T. Henderson, E. Kim, W.K. Hong, and R. Mass PhaseI/II study of the recombinant humanized monoclonal anti-VEGF antibody bevacizumab and the EGFR-TK inhibitor erlotinib in patients with recurrent non-small cell lung cancer (NSCLC) [abstract] Proc Am Soc Clin Oncol 22 2003 627
37. R.J. D'Amato, M.S. Loughnan, E. Flynn, and J. Folkman Thalidomide is an inhibitor of angiogenesis Proc Natl Acad Sci U S A 91 9 1994 4082 4085
38. J. Merchant, L. Hammes, M. Larson, D. Brophy, G. Ripple, and M. Mehta Pilot and safety trial of carboplatin, paclitaxel and thalidomide in advanced non-small cell lung cancer [abstract] Proc. Am Soc Clin Oncol 18 2000 541a
39. A.K. Sills Jr, J.I. Williams, B.M. Tyler, D.S. Epstein, E.P. Sipos, and J.D. Davis Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature Cancer Res 58 13 1998 2784 2792
40. F.R. Khuri, H. Wu, J.J. Lee, B.L. Kemp, R. Lotan, and S.M. Lippman Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer Clin Cancer Res 7 4 2001 861 867
41. C. Gridelli, P. Maione, G. Airoma, and A. Rossi Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer Curr Med Chem 9 21 2002 851 858
42. N.K. Altorki, R.S. Keresztes, J.L. Port, D.B. Flieder, C.A. Ferrara, and M.W. Pasmantier Celecoxib (celebrex), a selective COX-2 inhibitor, enhances the response to preoperative paclitaxel/carboplatin in early stage non-small cell lung cancer [abstract] Proc. Am Soc Clin Oncol 21 2002 26a
43. S.C. Stani, G. Mansueto, G. Comella, F. Ferrau', B. Capaccetti, and G. Carillio Antiangiogenic therapy with celecoxib and weekly paclitaxel as second line treatment for advanced non small cell lung cancer (NSCLC): a phase II study [abstract] Proc Am Soc Clin Oncol 22 2003 687
44. D.H. Johnson, I. Csiki, A. Gonzalez, D.P. Carbone, S. Gautam, and N. Campbell Cyclooxygenase-2 (COX-2) inhibition in non-small cell lung cancer (NSCLC): preliminary results of a phase II trial [abstract] Proc Am Soc Clin Oncol 22 2003 640
45. D. Ingber, T. Fujita, S. Kishimoto, K. Sudo, T. Kanamaru, and H.D. Brem Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth Nature 3489 6301 1990 555 557
46. B.A. Teicher, S.A. Holden, G. Ara, T. Korbut, and K. Menon Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma Cancer Chemother Pharmacol 38 2 1996 169 177
47. B.A. Teicher, N.P. Dupuis, M.F. Robinson, Y. Emi, and D.A. Goff Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma Oncol Res 7 5 1995 237 243
48. R.S. Herbst, H. Takeuchi, and B.A. Teicher Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models Cancer Chemother Pharmacol 41 6 1998 497 504
49. R.S. Herbst, T.L. Madden, H.T. Tran, G.R. Blumenschein Jr, C.A. Meyers, and L.F. Seabrooke Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer J Clin Oncol 20 22 2002 4440 4447
50. F.A. Shepherd, G. Giaccone, L. Seymour, C. Debruyne, A. Bezjak, and V. Hirsh Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the national cancer institute of Canada-clinical trials group and the European organization for research and treatment of cancer J Clin Oncol 20 22 2002 4434 4439
51. C. Erlichman, A.A. Adjei, S.R. Alberts, J.A. Sloan, R.M. Goldberg, and H.C. Pitot Phase I study of the matrix metalloproteinase inhibitor, BAY 12â€"9566 Ann Oncol 12 3 2001 389 395
52. H. Hurwitz, S.N. Holden, S.G. Eckhardt, M. Rosenthal, R. de Boer, and D. Rischin Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling in patients with solid tumors [abstract] Proc. Am Soc Clin Oncol 21 2002 82
53. R.A. Ezekowitz, J.B. Mulliken, and J. Folkman Interferon alfa-2a therapy for life-threatening hemangiomas of infancy N Engl J Med 326 22 1992 1456 1463
54. F.A. Shepherd, R. Beaulieu, K. Gelmon, C.A. Thuot, C. Sawka, and S. Read A prospective randomized trial of tow dose levels of interferon-alpha and zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection J Clin Oncol 16 1998 1736 1742
55. K. Kelly, J.J. Crowley, P.A. Bunn Jr, M.B. Hazuka, K. Beasley, and C. Upchurch Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study J Clin Oncol 13 12 1995 2924 2930
56. J.R. Jett, A.W. Maksymiuk, J.Q. Su, J.A. Mailliard, J.E. Krook, and L.K. Tschetter Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer J Clin Oncol 12 11 1994 2321 2326
57. K. Mattson, A. Niiranen, S. Pyrhonen, L.R. Holsti, P. Holsti, and E. Kumpulainen Natural interferon alfa as maintenance therapy for small cell lung cancer Eur J Cancer 28A 8â€"9 1992 1387 1391
58. B. Lebeau, P. De. L. Salmoniere, G. Ozenne, F. Blanchon, P. Leclerc, and D. Coetmeur Alpha interferon as maintenance therapy for small cell lung cancer (SCLC) [abstract] Proc. Am Soc Clin Oncol 18 1999 475a
59. S.M. Lee, L.E. James, V. Mohamed-Ali, C. Boschoff, M. Snee, and C. Brock A phase II study of carboplatin/etoposide with thalidomide in small cell lung cancer (SCLC) [abstract] Proc. Am Soc Clin Oncol 21 2002 313a
60. X. Quantin, W. Jacot, and M.C. Bozonnat Lung Cancer 37 Suppl 1 2002 S46
61. C.R. Parish, C. Freeman, K.J. Brown, D.J. Francis, and W.B. Cowden Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity Cancer Res 59 14 1999 3433 3441
62. F.H. Blackhall, C.L. Merry, E.J. Davies, and G.C. Jayson Heparan sulfate proteoglycans and cancer Br J Cancer 85 8 2001 1094 1098
63. S.N. Holden, M. Basche, L. Gore, M. Persky, J. Hunt, and CL O'Bryant A phase I study of the heparanase inhibitor PI-88 and weekly docetaxel in patients (pts) with advanced solid malignancies [abstract] Proc Am Soc Clin Oncol 22 2003 640
64. T.A. Fong, L.K. Shawver, L. Sun, C. Tang, H. App, and T.J. Powell SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types Cancer Res 591 1999 99 106
65. F.H. Blackhall, M. Pintilie, M. Michael, N. Leighl, R. Feld, and M.S. Tsao Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer Clin Cancer Res 9 6 2003 2241 2247
66. G.W. Krystal, S. Honsawek, D. Kiewlich, C. Liang, S. Vasile, and L. Sun Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells Cancer Res 61 9 2001 3660 3668
67. L. Rosen, M. Mulay, A. Mayers, F. Kabbinavar, P. Rosen, and G. Cropp Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies [abstract] Proc Am Soc Clin Oncol 18 1999 161a
68. B.C. Kuenen, L. Rosen, E.F. Smit, M.R. Parson, M. Levi, and R. Ruijter Dose-finding and pharmacokinetic study of cisplatin, gemcitibine, and SU5416 in patients with solid tumors J Clin Oncol 20 6 2002 1657 1667
69. R.S. Herbst, M. Hidalgo, A.S. Pierson, S.N. Holden, M. Bergen, and S.G. Eckhardt Angiogenesis inhibitors in clinical development for lung cancer Semin Oncol 29 1 Suppl 4 2002 66 77
70. E. Raymond, S. Faivre, K. Vera, C. Delbaldo, C. Robert, and A. Spatz Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers [abstract] Proc Am Soc Clin Oncol 22 2003 192
71. A.W. Tolcher, J.J. O'Leary, J.S. DeBono, J.D. Caulkins, K. Molpus, and K. Sutula A phase I and biologic correlative study of an oral endothelial vascular growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632 in patients with advanced solid tumors Proc Am Soc Clin Oncol 21 2002 84a
72. W.G. Roberts, J. Jani, J. Beebe, E. Emerson, T. Grant, and P. Goodwin Preclinical development of CP-547,632, a novel VEGFR-2 inhibitor for cancer therapy [abstract] Proc Am Soc Clin Oncol 21 2002 119a
73. M.S. O'Reilly, T. Boehm, Y. Shing, N. Fukai, G. Vasios, and W.S. Lane Endostatin: an endogenous inhibitor of angiogenesis and tumor growth Cell 88 2 1997 277 285
74. T. Boehm, J. Folkman, T. Browder, and M.S. O'Reilly Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance Nature 390 6658 1997 404 407
75. R.S. Herbst, K.R. Hess, H.T. Tran, J.E. Tseng, N.A. Mullani, and C. Charnsangavej Phase I study of recombinant human endostatin in patients with advanced solid tumors J Clin Oncol 20 18 2002 3792 3803
76. A.S. Boehle, R. Kurdow, M. Schulze, U. Kliche, B. Sipos, and K. Soondrum Human endostatin inhibits growth of human non-small-cell lung cancer in a murine xenotransplant model Int J Cancer 94 3 2001 420 428
77. M.S. Gordon, D. Mendelson, M.S. Guirguis, R.A. Knight, R.A. Humerickhouse, and A. Stopeck ABT-510, an anti-angiogenic, thrombospondin-1 (TSP-1) mimetic peptide, exhibits favorable safety profile and early signals of activity in a randomized phase IB trial [abstract] Proc Am Soc Clin Oncol 22 2003 195
78. J.H. Bilenker, J.P. Stevenson, M.A. Rosen, M. Gallagher, K.T. Flaherty, and K.M. Algazy Phase Ib trial of combretastatin A-4 phosphate (CA4P) in combination with carboplatin in patients with advanced cancer [abstract] Proc Am Soc Clin Oncol 223 2003 222
79. H. Goto, S. Yano, H. Zhang, Y. Matsumori, H. Ogawa, and D.C. Blakey Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice Cancer Res 62 13 2002 3711 3715
80. D.W. Siemann, and A.M. Rojiani Enhancement of radiation therapy by the novel vascular targeting agent ZD6126 Int J Radiat Oncol Biol Phys 53 1 2002 164 171
81. S.M. Gadgeel, P.M. LoRusso, A.J. Wozniak, and C. Wheeler A dose-escalation study of the novel vascular-targeting agent, ZD6126, in patients with solid tumors [abstract] Proc Am Soc Clin Oncol 21 2002 110a
82. S.A. Radema, L.V. Beerepoot, P.O. Witteveen, M.F. Gebbink, C. Wheeler, and E.E. Voest Clinical evaluation of the novel vascular-targeting agent, ZD6126: assessment of toxicity and surrogate markers of vascular damage [abstract] Proc Am Soc Clin Oncol 21 2002 110a
83. S.S. Smyth, and C. Patterson Tiny dancers: the integrin-growth factor nexus in angiogenic signaling J Cell Biol 158 1 2002 17 21
84. C.C. Kumar, M. Malkowski, Z. Yin, E. Tanghetti, B. Yaremko, and T. Nechuta Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist Cancer Res 61 5 2001 2232 2238
85. F. Eskens, H. Dumez, J. Verweij, A. Perschl, A. Kovar, and C. Brindley Phase I and pharmacologic study of EMD 121974, an alphaV3 and alphaVB5 integrin inhibitor that perturbs tumor angiogenesis, in patients with solid tumors [abstract] Proc. Am Soc Clin Oncol 19 2000 206a
86. S.N. Holden, M. Morrow, C. O'Bryant, J. Pluda, and S.G. Eckhardt Correlative biological assays used to guide dose escalation in a phase I study of the antiangiogenic aVB3 and a VB5 integrin antagonist EMD 121974 (EMD) [abstract] Proc. Am Soc Clin Oncol 21 2002 28a
87. B.B. Ma, C.D. Britten, and L.L. Siu Clinical trial designs for targeted agents Hematol Oncol Clin North Am 16 5 2002 1287 1305
88. M. Balbin, A. Fueyo, A.M. Tester, A.M. Pendas, A.S. Pitiot, and A. Astudillo Loss of collagenase-2 confers increased skin tumor susceptibility to male mice Nat Genet 35 3 2003 252 257
89. H.L. Anderson, J.T. Yap, M.P. Miller, A. Robbins, T. Jones, and P.M. Price Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate J Clin Oncol 21 15 2003 2823 2830
90. W. Wolf, C.A. Presant, V. Waluch, and B.J. Leberthon A unique methodology using dynamic contrast enhanced MRI (DEMRI) for quantifying antiangiogenic effects (AAE) of chemotherapy: AAE of docetaxel (DOC) correlate with tumor response (TR) [abstract] Proc Am Soc Clin Oncol 22 2003 206
91. D.H. Johnson Gefitinib (iressa) trials in non-small cell lung cancer Lung Cancer 41 Suppl 1 2003 S23 S28
92. D.S. Grant, T.L. Williams, M. Zahaczewsky, and A.P. Dicker Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere) Int J Cancer 104 1 2003 121 129
93. F.A. Shepherd, J. Dancey, R. Ramlau, K. Mattson, R. Gralla, and M O'Rourke Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 10 2000 2095 2103